Could a daily shot help kids with obesity lose weight?

NCT ID NCT04775082

Ongoing Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 28 times

Summary

This study tests whether the drug liraglutide, already approved for adults, can help children aged 6 to 12 with obesity lose weight. About 78 children will receive either liraglutide or a placebo injection daily for 56 weeks, along with counseling on diet and exercise. Researchers will measure changes in body mass index (BMI) and monitor for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Barry J. Reiner, MD LLC

Baltimore, Maryland, 21229, United States
CUF-Porto

Porto, 4100-180, Portugal
Centro Hospitalar Lisboa Norte

Lisbon, 1649-035, Portugal
Children's Hospital Colorado

Denver, Colorado, 80045, United States
Consultorio de Endocrinología y Pediatría

Puebla City, 72190, Mexico
Endolife Specialty Hospitals

Guntur, Andhra Pradesh, 522001, India
FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia

Moscow, 117292, Russia
Hospital CUF Porto S.A.

Porto, 4100-180, Portugal
Hospital Putrajaya

Putrajaya, 62250, Malaysia
Hospital da Luz

Lisbon, 1500-650, Portugal
Hospital da Luz Lisboa, S.A.

Lisbon, 1500-650, Portugal
Kantonsspital Olten

Olten, 4600, Switzerland
Kinderspital Endokrinologie, Zürich

Zurich, 8032, Switzerland
Mamc & Lnjp

New Delhi, 110002, India
NSMU paediatric clinic

Novosibirsk, 630048, Russia
Pennington Biom Res Ctr

Baton Rouge, Louisiana, 70808, United States
PriMed Clinical Research

Dayton, Ohio, 45419, United States
Rambam MC - Department of Pediatrics A

Haifa, 31096, Israel
Samara Regional Children Clinical Hospital n.a. N.N. Ivanova

Samara, 443079, Russia
Schneider MC - Endrocrinology and Diabetes

Petah Tikva, 49202, Israel
Siberian State Medical University

Tomsk, 634050, Russia
Solaris Clinical Research

Meridian, Idaho, 83646, United States
TMC Hlthcr Clin Res Office

Tucson, Arizona, 85712, United States
UBMD Peds-Div of Endo/Diabetes

Buffalo, New York, 14203, United States
ULS De Santo António, E.P.E. - Hospital de Santo António

Porto, 4099-001, Portugal
UPMC Child Hosp-Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States
UZ Brussel

Brussels, 1090, Belgium
UZ Leuven - Kindergeneeskunde

Leuven, 3000, Belgium
Unidade De Santa Maria E.P.E. - Hospital de Santa Maria

Lisbon, 1649-035, Portugal
Unidade Local de Saúde de Santo António, E.P.E

Porto, 4099-001, Portugal
University Malaya Medical Centre

Lembah Pantai, Kuala Lumpur, 59100, Malaysia
University of Minnesota_CPOM

Minneapolis, Minnesota, 55414, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

liraglutide

What this could lead to

If successful, this could provide a new medication option to help children with obesity lose weight, potentially reducing future health risks.

What could go wrong

This is a relatively small, early-phase trial. Liraglutide may cause side effects like nausea or vomiting, and weight loss may not be sustained long-term. Results may not apply to all children.

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY